North Annette 4
4 · Turning Point Therapeutics, Inc. · Filed Jun 16, 2021
Insider Transaction Report
Form 4
North Annette
EVP, General Counsel & Secty.
Transactions
- Sale
Common Stock
2021-06-15$77.37/sh−2,700$208,899→ 18,999 total - Sale
Common Stock
2021-06-15$77.82/sh−6,634$516,258→ 12,365 total - Exercise/Conversion
Common Stock
2021-06-15$17.00/sh+15,000$255,000→ 27,365 total - Sale
Common Stock
2021-06-15$75.94/sh−5,666$430,276→ 21,699 total - Exercise/Conversion
Stock Option (right to buy)
2021-06-15−15,000→ 154,609 totalExercise: $17.00Exp: 2029-04-14→ Common Stock (15,000 underlying)
Footnotes (5)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
- [F2]The weighted average sale price for the transaction reported was $75.94, and the range of prices were between $75.49 and $76.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $77.37, and the range of prices were between $76.575 and $77.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $77.82, and the range of prices were between $77.59 and $78.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested.